The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
Open accessAbstract
Genes mutated in patients with Fanconi anemia (FA) interact with the DNA repair genes BRCA1 and BRCA2/FANCD1 to suppress tumorigenesis, but the molecular functions ascribed to them cannot fully explain all of their cellular roles. Here, we show a repair-independent requirement for FA genes, including FANCD2, and BRCA1 in protecting stalled replication forks from degradation. Fork protection is surprisingly rescued in FANCD2-deficient cells by elevated RAD51 levels or stabilized RAD51 filaments. Moreover, FANCD2-mediated fork protection is epistatic with RAD51 functions, revealing an unanticipated fork protection pathway that connects FA genes to RAD51 and the BRCA1/2 breast cancer suppressors. Collective results imply a unified molecular mechanism for repair-independent functions of FA, RAD51, and BRCA1/2 proteins in preventing genomic instability and suppressing tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BRCA1 is implicated in a repair-independent mechanism in protecting stalled replication forks from degradation to maintain genome stability (Schlacher et al., 2012).”
From The BRCA1-Interacting Protein Abraxas Is Required for Genomic Stability and Tumor Suppression (2014) · cites this paper as Schlacher et al., 2012
In the citing paper
“As previously shown, BRCA1-deficient cells show significant shortening of fork length following hydroxyurea (HU) treatment indicating degradation of stalled replication forks.”
From The BRCA1-Interacting Protein Abraxas Is Required for Genomic Stability and Tumor Suppression (2014) · cites this paper as Schlacher et al., 2012
In the citing paper
“In addition, Abraxas did not appear to be required for efficient replication restart after HU treatment (data not shown), consistent with published observation that BRCA1 is not required for replication recovery (Schlacher et al., 2012).”
From The BRCA1-Interacting Protein Abraxas Is Required for Genomic Stability and Tumor Suppression (2014) · cites this paper as Schlacher et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., & Jasin, M. (2011) · Cell · doi:10.1016/j.cell.2011.03.041 · Cited by 1,292
Self-citationBrca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
Self-citationInteraction of the Fanconi Anemia Proteins and BRCA1 in a Common Pathway
Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M. S., Timmers, C., Hejna, J., Grompe, M., & D'Andrea, A. D. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00173-3 · Cited by 1,198
Nucleotide deficiency promotes genomic instability in early stages of cancer development
Bester, A. C., Roniger, M., Oren, Y. S., Im, M. M., Sarni, D., Chaoat, M., Bensimon, A., Zamir, G., Shewach, D. S., & Kerem, B. (2011) · Cell · doi:10.1016/j.cell.2011.03.044 · Cited by 858
Advanced pancreatic carcinoma: current treatment and future challenges
Stathis, A., & Moore, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.236 · Cited by 791
Chen, J., Silver, D. P., Walpita, D., Cantor, S. B., Gazdar, A. F., Tomlinson, G. E., Couch, F. J., Weber, B. L., Ashley, T., Livingston, D. M., et al. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80276-2 · Cited by 635
How the Fanconi Anemia Pathway Guards the Genome
Moldovan, G., & D’Andrea, A. D. (2009) · Annual Review of Genetics · doi:10.1146/annurev-genet-102108-134222 · Cited by 601
Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis
Hashimoto, Y., Chaudhuri, A. R., Lopes, M., & Costanzo, V. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1927 · Cited by 537
The Fanconi Anemia Pathway Promotes Replication-Dependent DNA Interstrand Cross-Link Repair
Knipscheer, P., Räschle, M., Smogorzewska, A., Enoiu, M., Ho, T. V., Schärer, O. D., Elledge, S. J., & Walter, J. C. (2009) · Science · doi:10.1126/science.1182372 · Cited by 525
Research works printed but not linked: 1
- Schroeder, 1964, [Spontaneous chromosome aberrations in familial panmyelopathy], Humangenetik, 1, 194
Cited by
Sorted by citations
Items 601–700 of 930
Characterization of the recombination activities of the Entamoeba histolytica Rad51 recombinase
Kelso, A. A., Goodson, S. D., Chavan, S. A., Say, A. F., Turchick, A., Sharma, D., Ledford, L. L., Ratterman, E., Leskoske, K. L., King, A. V., et al. (2016) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2016.09.001 · Cited by 13
Federico, M. B., Siri, S. O., Calzetta, N. L., Paviolo, N. S., de la Vega, M. B., Martino, J., Campana, M. C., Wiesmüller, L., & Gottifredi, V. (2020) · Oncogene · doi:10.1038/s41388-020-1265-9 · Cited by 12
Wu, C.-K., Shiu, J.-L., Wu, C., Hung, C.-F., Ho, Y.-C., Chen, Y., Tung, S.-Y., Yeh, C.-F., Shen, C., Liaw, H., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae211 · Cited by 12
Dixit, S., Nagraj, T., Bhattacharya, D., Saxena, S., Sahoo, S., Chittela, R. K., Somyajit, K., & Nagaraju, G. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114594 · Cited by 12
Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers
Moser, S. C., & Jonkers, J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1326 · Cited by 13
Bhattacharya, D., Dwivedi, H. K., & Nagaraju, G. (2025) · EMBO Reports · doi:10.1038/s44319-025-00497-3 · Cited by 12
What Combined Measurements From Structures and Imaging Tell Us About DNA Damage Responses
Brosey, C. A., Ahmed, Z., Lees‐Miller, S. P., & Tainer, J. A. (2017) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.04.005 · Cited by 12
MT1-MMP-dependent ECM processing regulates laminB1 stability and mediates replication fork restart
Thakur, V., de Freitas, J. T., Li, Y., Zhang, K., Savadelis, A., & Bedogni, B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253062 · Cited by 12
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer
Palleschi, M., Tedaldi, G., Sirico, M., Virga, A., Ulivi, P., & Giorgi, U. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157884 · Cited by 13
Katsuki, Y., Abe, M., Park, S. Y., Wu, W., Yabe, H., Yabe, M., van Attikum, H., Nakada, S., Ohta, T., Seidman, M. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109879 · Cited by 12
Batenburg, N. L., Mersaoui, S. Y., Walker, J. R., Coulombe, Y., Hammond-Martel, I., Würtele, H., Masson, J., & Zhu, X. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1173 · Cited by 12
Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia
Chihanga, T., Vicente-Muñoz, S., Ruiz-Torres, S., Pal, B., Sertorio, M. G., Andreassen, P. R., Khoury, R. A., Mehta, P. A., Davies, S. M., Lane, A. N., et al. (2022) · Cancers · doi:10.3390/cancers14082040 · Cited by 12
Peña-Gómez, M. J., Moreno-Gordillo, P., Narmontė, M., García-Calderón, C. B., Rukšėnaitė, A., Klimašauskas, S., & Rosado, I. V. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04952-0 · Cited by 12
Martino, J., Siri, S. O., Calzetta, N. L., Paviolo, N. S., Garro, C., Pansa, M. F., Carbajosa, S., Brown, A. C., Bocco, J. L., Gloger, I., et al. (2023) · eLife · doi:10.7554/elife.80254 · Cited by 12
SIN3A histone deacetylase action counteracts MUS81 to promote stalled fork stability
Muñoz, S., Barroso, S. I., Badra-Fajardo, N., Marqueta-Gracia, J. J., García-Rubio, M. L., Ubieto‐Capella, P., Méndez, J., & Aguilera, A. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113778 · Cited by 12
Oda, Y., Hidaka, M., & Suzuki, A. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00457 · Cited by 12
A new road to cancer-drug resistance
Schlacher, K. (2018) · Nature · doi:10.1038/d41586-018-07188-1 · Cited by 12
Self-citationProlyl isomerization of FAAP20 catalyzed by PIN1 regulates the Fanconi anemia pathway
Wang, J., Chan, B. K., Tong, M., Paung, Y., Jo, U., Martin, D. W., Seeliger, M. A., Haley, J. D., & Kim, H. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1007983 · Cited by 12
Homologous recombination defects and how they affect replication fork maintenance
Son, M. Y., & Hasty, P. (2018) · Global Medical Genetics · doi:10.3934/genet.2018.4.192 · Cited by 14
Aiello, F. A., Palma, A., Malacaria, E., Zheng, L., Campbell, J. L., Shen, B., Franchitto, A., & Pichierri, P. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz431 · Cited by 12
Role of HP1β during spermatogenesis and DNA replication
Charaka, V., Tiwari, A., PANDITA, R. K., Hunt, C. R., & Pandita, T. K. (2020) · Chromosoma · doi:10.1007/s00412-020-00739-4 · Cited by 12
O’Driscoll, M. (2016) · The Journal of Pathology · doi:10.1002/path.4828 · Cited by 12
Lewis, T., Barthelemy, J., Virts, E. L., Kennedy, F. M., Gadgil, R. Y., Wiek, C., Linka, R. M., Zhang, F., Andreassen, P. R., Hanenberg, H., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz026 · Cited by 12
Sharp, M. F., Murphy, V. J., van Twest, S., Tan, W., Lui, J., Simpson, K. J., Deans, A. J., & Crismani, W. (2020) · Scientific Reports · doi:10.1038/s41598-020-64868-7 · Cited by 12
Safeguarding genome stability: RASSF1A tumor suppressor regulates BRCA2 at stalled forks
Pefani, D., & O’Neill, E. E. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1035845 · Cited by 12
Jaiswal, R., Lei, K.-H., Chastain, M., Wang, Y., Shiva, O., Li, S., You, Z.-S., Chi, P., & Chai, W.-H. (2023) · Nature Communications · doi:10.1038/s41467-023-43685-2 · Cited by 9
Kovuru, N., Mochizuki‐Kashio, M., Menna, T. N., Jeffrey, G., Hong, Y., Yoon, Y. M., Zhang, Z., & Kurre, P. (2024) · Nature Communications · doi:10.1038/s41467-024-46159-1 · Cited by 11
RNF4 sustains Myc-driven tumorigenesis by facilitating DNA replication
Her, J., Zheng, H., & Bunting, S. F. (2024) · Journal of Clinical Investigation · doi:10.1172/jci167419 · Cited by 11
A RAD18–UBC13–PALB2–RNF168 axis mediates replication fork recovery in BRCA1-deficient cancer cells
Cybulla, E., Wallace, S., Meroni, A., Jackson, J., Agashe, S., Tennakoon, M., Limbu, M., Quinet, A., Lomonosova, E. E., Noia, H. M., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae563 · Cited by 11
The Fanconi anemia pathway repairs colibactin-induced DNA interstrand cross-links
Altshuller, M., Xu, H., MacKrell, E. J., Wernke, K. M., Airan, Y., Wong, J. W. H., Sellés‐Baiget, S., Wang, T., Chou, T., Duxin, J. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65606-1 · Cited by 12
Tomaszowski, K.-H., Roy, S., Guerrero, C., Shukla, P. D., Keshvani, C., Chen, Y., Ott, M., Wu, X., Zhang, J., Dinardo, C. D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36933-y · Cited by 12
Self-citationRegulation of Rad52-dependent replication fork recovery through serine ADP-ribosylation of PolD3
Richards, F., Llorca-Cardeñosa, M. J., Langton, J., Buch-Larsen, S. C., Shamkhi, N., Sharma, A. B., Nielsen, M. L., & Lakin, N. D. (2023) · Nature Communications · doi:10.1038/s41467-023-40071-w · Cited by 12
Kehrli, K., & Sidorova, J. M. (2014) · Oncoscience · doi:10.18632/oncoscience.70 · Cited by 11
Ko, J. H., Son, M. Y., Zhou, Q., Molnárová, L., Song, L., Mlčoušková, J., Je̅kabsons, A., Montagna, C., Krejčí, L., & Hasty, P. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108543 · Cited by 11
PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair
Ninou, A. H., Lehto, J., Chioureas, D., Stigsdotter, H., Schelzig, K., Åkerlund, E., Gudoitytė, G., Joneborg, U., Carlson, J. W., Jonkers, J., et al. (2021) · Cancers · doi:10.3390/cancers13143604 · Cited by 11
Pinto, L., Baidarjad, H., Entz‐Werlé, N., & Dyck, E. V. (2021) · Cancers · doi:10.3390/cancers13225678 · Cited by 12
Caeiro, L. D., Nakata, Y., Borges, R. L., Zha, M., Garcia-Martinez, L., Bañuelos, C. P., Stransky, S., Liu, T., Chan, H. L., Brabson, J., et al. (2024) · Genes & Development · doi:10.1101/gad.351408.123 · Cited by 11
Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer
Bi, R., Chen, L., Huang, M., Qiao, Z., Li, Z., Fan, G., & Wang, Y. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189221 · Cited by 11
Peña-Gómez, M. J., Rodríguez-Martín, Y., Oliva, M. D. R., Hanthi, Y. W., Berrada, S., Freire, R., Masson, J., Reyes, J. C., Costanzo, V., & Rosado, I. V. (2025) · Science Advances · doi:10.1126/sciadv.ads3227 · Cited by 10
DNA repair pathways in ovarian cancer: Implications for therapy and resistance
Miras, I., Gutiérrez, I. V., Estévez-García, P., & Muñoz-Galván, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118719 · Cited by 10
Xiang, J., Li, J., Guo, Z., Wu, J., Ma, D., Xu, H., Shang, T., Pu, P., Cong, L., Zhou, R., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00908-0 · Cited by 11
Yu, Y., Xu, W., Wen, C., Zhao, S., Li, G., Liu, R., Chen, Z., Qin, Y., Ma, J., Yang, Y., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04733-8 · Cited by 10
Degradation of Mrc1 promotes recombination-mediated restart of stalled replication forks
Chaudhury, I., & Koepp, D. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1249 · Cited by 11
Never tear us a-PARP: Dealing with DNA lesions during mitosis
Schoonen, P. M., & van Vugt, M. A. T. M. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1382670 · Cited by 10
Expression, Purification, and Biochemical Evaluation of Human RAD51 Protein
Subramanyam, S. V., & Spies, M. (2018) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.11.011 · Cited by 10
Kornberg, Z., Chou, J., Feng, F. Y.-C., & Ryan, C. J. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.06 · Cited by 10
Ding, J., Wu, S., Zhang, C., Garyali, A., Martínez-Ledesma, E., Gao, F., Pokkulandra, A., Li, X., Bristow, C. A., Carugo, A., et al. (2019) · PubMed Central · Cited by 10
The RECQL helicase prevents replication fork collapse during replication stress
Benedict, B., van Bueren, M. A. E., van Gemert, F. P. A., Lieftink, C., Llobet, S. G., van Vugt, M. A. T. M., Beijersbergen, R. L., & Riele, H. T. (2020) · Life Science Alliance · doi:10.26508/lsa.202000668 · Cited by 12
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications
McCann, K. E. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000517 · Cited by 10
Bold, I., Specht, A.-K., Droste, C. F., Zielinski, A., Meyer, F. B., Clauditz, T. S., Münscher, A., Werner, S., Rothkamm, K., Petersen, C., et al. (2021) · Cancers · doi:10.3390/cancers13061194 · Cited by 10
Willis, N. A., & Scully, R. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1172149 · Cited by 10
How to sensitize glioblastomas to temozolomide chemotherapy: a gap-centered view
Miramova, A., Gartner, A., & Ivanov, D. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1436563 · Cited by 9
Minuti, A., Mazzon, E., Iori, R., Chiricosta, L., & Artimagnella, O. (2024) · Nutrients · doi:10.3390/nu16234202 · Cited by 9
A medicinal chemistry perspective on ATR: Current status and future directions
Li, K., Sun, X., Liu, S., Liu, Y., Feng, X., & Zhang, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117834 · Cited by 10
Sasaki, M., & Kobayashi, T. (2022) · Genes & Genetic Systems · doi:10.1266/ggs.22-00046 · Cited by 9
The linker histone H1–BRCA1 axis is a crucial mediator of replication fork stability
Ozgencil, M., Dullovi, A., Higos, R., Hořejšı́, Z., & Bellelli, R. (2023) · Life Science Alliance · doi:10.26508/lsa.202301933 · Cited by 9
Human HELQ regulates DNA end resection at DNA double-strand breaks and stalled replication forks
Zhao, Y., Hou, K., Li, Y., Hao, S., Liu, Y., Na, Y., Li, C., Cui, J. G., Xu, X., Wu, X., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad940 · Cited by 10
R-loop functions in Brca1 -associated mammary tumorigenesis
Chiang, H.-C., Qi, L., Mitra, P., Huang, Y., Hu, Y., & Li, R. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403600121 · Cited by 9
Romero, N.-E., Matson, S. W., & Sekelsky, J. J. (2016) · Genetics · doi:10.1534/genetics.116.192534 · Cited by 9
Ghodke, I., & Muniyappa, K. (2016) · Journal of Biosciences · doi:10.1007/s12038-016-9642-9 · Cited by 10
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer
Rescigno, P., Chandler, R. W., & Bono, J. S. D. (2018) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000358 · Cited by 9
Špı́rek, M., Taylor, M. R. G., Beláň, O., Boulton, S. J., & Krejčí, L. (2021) · Nature Communications · doi:10.1038/s41467-021-25830-x · Cited by 10
Identification of Nanog as a novel inhibitor of Rad51
Xin, Y., Wang, J., Wu, Y., Li, Q., Dong, M., Liu, C., He, Q., Wang, R., Wang, D., Jiang, S., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04644-9 · Cited by 9
Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
Le, B. V., Podszywalow‐Bartnicka, P., Piwocka, K., & Skórski, T. (2022) · Cancers · doi:10.3390/cancers14235795 · Cited by 9
Do p53 stress responses impact organismal aging?
Hasty, P., Campisi, J., & Sharp, Z. D. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.12.02 · Cited by 9
Nucleases and Co-Factors in DNA Replication Stress Responses
Nickoloff, J. A., Sharma, N., Taylor, L. E., Allen, S. J., & Hromas, R. (2022) · DNA · doi:10.3390/dna2010006 · Cited by 9
FANCD2 Alleviates Physiologic Replication Stress in Fetal Liver HSCPreprint
Mochizuki‐Kashio, M., Yoon, Y. M., Menna, T. N., Grompe, M., & Kurre, P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.30.320796 · Cited by 9
Berrada, S., Martínez‐Balsalobre, E., Larcher, L., Azzoni, V., Vasquez, N., Costa, M. D., Abel, S., Audoly, G., Lee, L., Montersino, C., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad559 · Cited by 8
Batenburg, N. L., Sowa, D. J., Walker, J. R., Andres, S. N., & Zhu, X. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae154 · Cited by 8
Mu, A., Okamoto, Y., Katsuki, Y., & Takata, M. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103733 · Cited by 8
Mechanism of Action of PARP Inhibitors
Kim, C., & Yu, Y. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042324-103725 · Cited by 10
Homologous recombination deficiency (HRD) diagnostics: underlying mechanisms and new perspectives
Андреевич, К. А., Koryukov, M., Mikheeva, R., & Филипенко, М. Л. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10238-y · Cited by 8
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells
Zelceski, A., Francica, P., Lingg, L., Mutlu, M., Stok, C., Liptay, M., Alexander, J. J., Baxter, J. S., Brough, R., Gulati, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112484 · Cited by 9
Xu, W., Yang, Y., Yu, Y., Wen, C., Zhao, S., Cao, L., Zhao, S., Qin, Y., & Chen, Z. (2023) · BMC Biology · doi:10.1186/s12915-023-01676-1 · Cited by 8
Li, Y., He, R., Qin, X. Y., Zhu, Q., Ma, L., & Liang, X. (2024) · PeerJ · doi:10.7717/peerj.17251 · Cited by 8
van der Merwe, N. C., Buccimazza, I., Rossouw, B., Araujo, M., Ntaita, K. S., Schoeman, M., Vorster, K., Napo, K., Kotze, M. J., & Oosthuizen, J. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07362-2 · Cited by 9
Liu, Z., Jiang, H., Lee, S. Y., Kong, N., & Chan, Y. W. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114464 · Cited by 9
A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
Wang, K., Shrestha, R., Wyatt, A. W., Reddy, A., Lehár, J., Wang, Y., Lapuk, A. V., & Collins, C. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103050 · Cited by 8
Panichnantakul, P., Patel, A., Tse, E. Y. W., & Wyatt, H. D. M. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103156 · Cited by 8
Pham, M. M., Hinchcliff, E., Avila, M., & Westin, S. N. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000562 · Cited by 9
RAD51 is a druggable target that sustains replication fork progression upon DNA replication stress
Feu, S., Unzueta, F., Ercilla, A., Pérez‐Venteo, A., Jaumot, M., & Agell, N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266645 · Cited by 8
Targeting homologous recombination repair in cancer
Murfuni, I., & Rass, U. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00008-5 · Cited by 8
Thongthip, S., Conti, B. A., Lach, F. P., & Smogorzewska, A. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1810394 · Cited by 8
Tan, W., & Deans, A. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.11.042 · Cited by 8
Role of Cockayne Syndrome Group B Protein in Replication Stress: Implications for Cancer Therapy
Walker, J. R., & Zhu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810212 · Cited by 9
Zeinali, E., Mashayekhi, F., Farraj, R. A., Hasanni, T., Caron, M., Coulombe, Y., Fitieh, A. M., Glover, J. N. M., Masson, J., & Ismail, I. H. (2025) · Science Advances · doi:10.1126/sciadv.adv0381 · Cited by 8
Profiling BRCA1-BRCT interactions and their functional relevance at amino acid resolution
Mangkusaputra, V., Murachelli, A. G., Yu, Z., den Hollander, A., Menafra, R., Schreuder, A., Kloet, S. L., Sixma, T. K., & Noordermeer, S. M. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf848 · Cited by 7
The expanding roles of homologous recombination proteins in genome stability
Sassi, L., Marroquin, A. M., Waked, S., Ardizzoia, A., & Costanzo, V. (2026) · The EMBO Journal · doi:10.1038/s44318-025-00673-0 · Cited by 10
The RPA inhibitor HAMNO sensitizes Fanconi anemia pathway-deficient cells
Jang, S.-W., & Kim, J. M. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2074200 · Cited by 7
Classen, S., Rahlf, E., Jungwirth, J., Albers, N., Hebestreit, L. P., Zielinski, A., Poole, L., Groth, M., Koch, P., Liehr, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113363 · Cited by 7
Watanabe, K., Yamamoto, T., Fujita, T., Hino, S., Hino, Y., Yamazaki, K., Ohashi, Y., Sakuraba, S., Kono, H., Nakao, M., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adl6445 · Cited by 7
Modulation of the Fanconi anemia pathway via chemically induced changes in chromatin structure
Vierra, D. A., Garzon, J. L., Rego, M. A., Adroved, M. M., Mauro, M., & Howlett, N. G. (2017) · Oncotarget · doi:10.18632/oncotarget.19470 · Cited by 7
TP53 Haploinsufficiency Rescues Emergency Granulopoiesis in FANCC−/− Mice
Hu, L., Huang, W., Bei, L., Broglie, L. A., & Eklund, E. A. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700931 · Cited by 7
Paquin, K. L., Mamrak, N. E., Garzon, J. L., Cantres-Velez, J. A., Azzinaro, P. A., Vuono, E. A., Lima, K. E., Camberg, J. L., & Howlett, N. G. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00194-19 · Cited by 7
Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum
Lehto, J., Ninou, A. H., Chioureas, D., Jonkers, J., & Gustafsson, N. (2021) · Cancers · doi:10.3390/cancers13061442 · Cited by 7
Cyclin-Dependent Kinase-Mediated Phosphorylation of FANCD2 Promotes Mitotic Fidelity
Cantres-Velez, J. A., Blaize, J. L., Vierra, D. A., Boisvert, R. A., Garzon, J. L., Piraino, B., Tan, W., Deans, A. J., & Howlett, N. G. (2021) · Molecular and Cellular Biology · doi:10.1128/mcb.00234-21 · Cited by 8
Innate immunity mediator STING modulates nascent DNA metabolism at stalled forks in human cells
Nguyen, V. N., Brunon, S., Pavlova, M. N., Lazarchuk, P., Sharifian, R., & Sidorova, J. M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1048726 · Cited by 7
Mórocz, M., Qorri, E., Pekker, E., Tick, G., & Haracska, L. (2023) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2023.12.001 · Cited by 7
The Fanconi Anemia Pathway of DNA Repair and Human Cancer
Krishnan, V., Tay, L. S., & Ito, Y. (2015) · InTech eBooks · doi:10.5772/59995 · Cited by 7
Metadata
- Authors
- Schlacher, K., Wu, H., & Jasin, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- Corresponding author
- Schlacher, Katharina
- Jasin, Maria
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 22
- Issue
- 1
- Pages
- 106-116
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3954744
- OpenAlex
- W2096380982
- Cited by
- 936
- References
- 46
- Citations by year
- 2026: 40 · 2025: 56 · 2024: 80 · 2023: 70 · 2022: 69 · 2021: 91 · 2020: 86 · 2019: 63 · 2018: 83 · 2017: 74 · 2016: 87 · 2015: 53 · 2014: 50 · 2013: 27 · 2012: 7
- FWCI
- 17.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA121110, P01-CA94060, P01CA094060)
- National Institute of General Medical Sciences (R01 GM54668, R01GM054668)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- Fanconi anemia, replication fork protection, FANCD2, RAD51, BRCA1, BRCA2, DNA repair, epistasis, genomic instability, tumor suppression
- MeSH terms
- Cell Line, Transformed, DNA Replication, Fanconi Anemia, Humans, Genes, BRCA1, Genes, BRCA2, BRCA2 Protein, Genomic Instability, Rad51 Recombinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review